Cargando…

Add-on Therapy With the α-Blockers Tamsulosin and Naftopidil Improves Voiding Function by Enhancing Neuronal Activity in Prostatic Hyperplasia Rats

PURPOSE: Benign prostatic hyperplasia (BPH) impacts quality of life in men by causing lower urinary tract symptoms. α1-Adrenoceptor (α1-AR) blockers improve lower urinary tract symptoms. We investigated the efficacy of add-on therapy with α1-AR blockers on BPH rats. METHODS: Rats in the drug-treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ko, Il-Gyu, Hwang, Lakkyong, Jin, Jun-Jang, Kim, Sang-Hoon, Han, Jin Hee, Jeon, Jung Won, Cho, Sung Tae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Continence Society 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885138/ https://www.ncbi.nlm.nih.gov/pubmed/29609419 http://dx.doi.org/10.5213/inj.1836064.032

Ejemplares similares

Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia
por: Griwan, Mahavir Singh, et al.
Publicado: (2014)

A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement
por: Perumal, Chenthil, et al.
Publicado: (2015)

Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia
por: Masumori, Naoya
Publicado: (2011)

Three-year outcome analysis of alpha 1-blocker naftopidil for patients with benign prostatic hyperplasia in a prospective multicenter study in Japan
por: Masumori, Naoya, et al.
Publicado: (2016)

Effects of Tamsulosin on Urinary Bladder Function and Neuronal Activity in the Voiding Centers of Rats with Cyclophosphamide-induced Overactive Bladder
por: Kim, Sung-Eun, et al.
Publicado: (2012)

Add-on treatment with mirabegron may improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after tamsulosin monotherapy
por: Kang, Tae Wook, et al.
Publicado: (2020)

An animal study to compare the degree of the suppressive effects on the afferent pathways of micturition between tamsulosin and sildenafil
por: Kim, Sung-Eun, et al.
Publicado: (2013)

Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study
por: Chung, Mun Su, et al.
Publicado: (2017)

Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia
por: Chung, Jae-Wook, et al.
Publicado: (2011)

Effects of Tamsulosin on Premature Ejaculation in Men with Benign Prostatic Hyperplasia
por: Choi, Jae Hwi, et al.
Publicado: (2014)

Adenosine A(2A) Receptor Agonist Polydeoxyribonucleotide Alleviates Interstitial Cystitis-Induced Voiding Dysfunction by Suppressing Inflammation and Apoptosis in Rats
por: Ko, Il-Gyu, et al.
Publicado: (2021)

Randomized Controlled Trial to Compare the Safety and Efficacy of Naftopidil and Tamsulosin as Medical Expulsive Therapy in Combination With Prednisolone for Distal Ureteral Stones
por: Kumar, Santosh, et al.
Publicado: (2013)

Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder
por: Wang, Hui, et al.
Publicado: (2017)

Evaluation of intermittent tamsulosin in treating symptomatic patients with benign prostatic hyperplasia
por: Soliman, Mohamed G., et al.
Publicado: (2023)

Cost-Effectiveness of Tamsulosin, Doxazosin, and Terazosin in the Treatment of Benign Prostatic Hyperplasia
por: Ohsfeldt, Robert L., et al.
Publicado: (2004)

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia
por: Zhou, Zhongbao, et al.
Publicado: (2019)

Efficacy of combination therapy with tamsulosin and zolpidem on nocturia in patients with benign prostatic hyperplasia
por: Miwa, Kousei, et al.
Publicado: (2011)

Effects of Combination Treatment of Alpha 1-Adrenergic Receptor Antagonists on Voiding Dysfunction: Study on Target Organs in Overactive Bladder Rats
por: Ko, Il Gyu, et al.
Publicado: (2016)

Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
por: Eisen, Christoph, et al.
Publicado: (2020)

Effects of Low-Dose Tamsulosin on Sexual Function in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
por: Kim, Sin Wook, et al.
Publicado: (2013)

Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil?
por: Tanuma, Yasushi, et al.
Publicado: (2016)

Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial
por: Pande, Satabdi, et al.
Publicado: (2014)

Letter to the Editor: Commentary on “Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients”
por: Tae, Bum Sik, et al.
Publicado: (2017)

Treadmill exercise ameliorates impairment of spatial learning memory in pups born to old and obese mother rats
por: Kim, Sang-Hoon, et al.
Publicado: (2021)

Short-term Effect of Tamsulosin and Finasteride Monotherapy and their Combination on Nigerian Men with Benign Prostatic Hyperplasia
por: Odusanya, Benjamin O, et al.
Publicado: (2017)

Scolopendra subspinipes mutilans Extract Suppresses Inflammatory and Neuropathic Pain In Vitro and In Vivo
por: Hwang, Lakkyong, et al.
Publicado: (2018)

Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients
por: Kim, Su Jin, et al.
Publicado: (2017)

The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study
por: Tanuma, Yasushi, et al.
Publicado: (2017)

A 52‐week multicenter randomized controlled study of the efficacy and safety of add‐on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study)
por: Yamanishi, Tomonori, et al.
Publicado: (2018)

Beneficial Effect of Increasing the Dose of Tamsulosin to 0.4 mg in Japanese Patients with Benign Prostatic Hyperplasia
por: Hirose, Yasuhiko, et al.
Publicado: (2011)

Additive effect of oral LDD175 to tamsulosin and finasteride in a benign prostate hyperplasia rat model
por: Choi, Bo Ram, et al.
Publicado: (2018)

Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis
por: Cai, Tong, et al.
Publicado: (2020)

Evaluation of Voiding Position on Uroflowmetry Parameters and Post Void Residual Urine in Patients With Benign Prostatic Hyperplasia and Healthy Men
por: Alrabadi, Adel, et al.
Publicado: (2020)

Polydeoxyribonucleotide Ameliorates Inflammation and Apoptosis in Achilles Tendon-Injury Rats
por: Rho, Jeong Ho, et al.
Publicado: (2020)

The Role of Alpha Blockers in Children with Dysfunctional Voiding
por: Austin, Paul F.
Publicado: (2009)

Study on the pathogenesis of liver injury caused by alcohol and drugs
por: Kim, Sang-Hoon, et al.
Publicado: (2021)

Treadmill exercise ameliorates ethanol with lipopolysaccharide and carbon tetrachloride-mediated liver injury in mice
por: Kim, Sang-Hoon, et al.
Publicado: (2022)

Polydeoxyribonucleotide Exerts Therapeutic Effect by Increasing VEGF and Inhibiting Inflammatory Cytokines in Ischemic Colitis Rats
por: Kim, Sung-Eun, et al.
Publicado: (2020)

Adenosine A(2A) receptor agonist polydeoxyribonucleotide ameliorates short-term memory impairment by suppressing cerebral ischemia-induced inflammation via MAPK pathway
por: Ko, Il-Gyu, et al.
Publicado: (2021)

The Authors Reply: Reply on “Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients”
por: Kim, Su Jin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_epkt8qqqq91tmb7gp4bmkeqhhv